Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, Version 2.2013

(2017) Margaret R. O’Donnell et al.   Journal of the National Comprehensive Cancer Network

G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

(2015) Pamela S. Becker et al.   AMERICAN JOURNAL OF HEMATOLOGY

A multigene array for measurable residual disease detection in AML patients undergoing SCT

(2015) M Goswami et al.   BONE MARROW TRANSPLANTATION

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

(2015) Naveen Pemmaraju et al.   Clinical Lymphoma Myeloma & Leukemia

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

(2015) Quan-shun Wang et al.   MOLECULAR THERAPY

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

(2014) Sarah L. Sammons et al.   AMERICAN JOURNAL OF HEMATOLOGY

Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

(2014) Naveen Pemmaraju et al.   AMERICAN JOURNAL OF HEMATOLOGY

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

(2014) Enrico De Astis et al.   ANNALS OF HEMATOLOGY

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

(2014) Akiyoshi Takami et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts

(2014) Anna Maria Raiola et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Targeted diphtheria toxin to treat BPDCN

(2014) D. J. FitzGerald   BLOOD

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

(2014) H. K. Lee et al.   BLOOD

The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV

(2014) M. J. Murai et al.   BLOOD

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

(2014) D. Grimwade et al.   BLOOD

Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis

(2014) M. Tan et al.   BLOOD

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

(2014) T. Umezu et al.   BLOOD

Extracellular nucleotide and nucleoside signaling in vascular and blood disease

(2014) M. Idzko et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML

(2014) M Sébert et al.   BONE MARROW TRANSPLANTATION

Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation

(2014) N Bejanyan et al.   BONE MARROW TRANSPLANTATION

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia

(2014) Anjali S. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

(2014) Jorge E. Cortes et al.   CANCER

Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

(2014) D. Steinbach et al.   CLINICAL CANCER RESEARCH

Primacy of Resistance Rather Than Toxicity in Determining Outcome of Therapy for AML

(2014) Elihu H. Estey   Clinical Lymphoma Myeloma & Leukemia

Gemtuzumab ozogamicin in acute myeloid leukemia revisited

(2014) Felicitas Thol et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Targeting FLT3 to treat leukemia

(2014) Heiko Konig et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

(2014) J. E. Lancet et al.   HAEMATOLOGICA

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

(2014) Gail J. Roboz et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

(2014) R B Walter et al.   LEUKEMIA

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

(2014) S J Busfield et al.   LEUKEMIA

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues

(2014) M Goswami et al.   LEUKEMIA

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

(2014) K. Keegan et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)

(2014) Geoffrey Uy et al.   Journal for ImmunoTherapy of Cancer

5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

(2013) Sarah Ivanoff et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcome of older patients with acute myeloid leukemia in first relapse

(2013) Clémentine Sarkozy et al.   AMERICAN JOURNAL OF HEMATOLOGY

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

(2013) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse

(2013) Sylvain Pilorge et al.   AMERICAN JOURNAL OF HEMATOLOGY

Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience

(2013) Wenjuan Yu et al.   ANNALS OF HEMATOLOGY

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

(2013) Bernard Tawfik et al.   ANNALS OF HEMATOLOGY

Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation

(2013) Christopher S. Hourigan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

(2013) I. Ben-Batalla et al.   BLOOD

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

(2013) E. I. Zimmerman et al.   BLOOD

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

(2013) I. Gojo et al.   CLINICAL CANCER RESEARCH

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

(2013) R. B. Walter et al.   HAEMATOLOGICA

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

(2013) Michael R. Grunwald et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

(2013) Jorge Cortes et al.   LANCET ONCOLOGY

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

(2013) S Park et al.   LEUKEMIA

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

A phase I study of decitabine and rapamycin in relapsed/refractory AML

(2013) Jane L. Liesveld et al.   LEUKEMIA RESEARCH

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

(2013) A. G. Chapuis et al.   Science Translational Medicine

Personalized Therapy for Acute Myeloid Leukemia

(2013) C. S. Hourigan et al.   Cancer Discovery

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs

(2013) Juliana Meyers et al.   Applied Health Economics and Health Policy

Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients

(2012) Barbara Scappini et al.   AMERICAN JOURNAL OF HEMATOLOGY

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

(2012) A. Eghtedar et al.   BLOOD

Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience

(2012) H. Itonaga et al.   BLOOD

A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities

(2012) Yiming Chen et al.   Clinical Lymphoma Myeloma & Leukemia

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

(2012) P. S. Becker et al.   HAEMATOLOGICA

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

(2011) J. E. Karp et al.   BLOOD

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

(2011) Pamela S. Becker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluation of Current Cancer Immunotherapy

(2011) Christopher S. Hourigan et al.   CANCER JOURNAL

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2011) Eric J. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

(2011) J E Lancet et al.   LEUKEMIA

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

(2011) Steven M. Trifilio et al.   LEUKEMIA RESEARCH

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience

(2010) Holbrook E. Kohrt et al.   AMERICAN JOURNAL OF HEMATOLOGY

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

(2010) S. Kurosawa et al.   HAEMATOLOGICA

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia

(2010) Bob Löwenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure

(2010) Michel Duval et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

(2010) A Shimoni et al.   LEUKEMIA

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens

(2010) Samantha L. Price et al.   LEUKEMIA RESEARCH

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia

(2009) Paul M. Armistead et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells

(2009) Masayoshi Kobune et al.   CANCER SCIENCE

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

(2009) Se Ryeon Lee et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia

(2007) Z. Xiang et al.   BLOOD